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Recurrentovariancancerisalethaldisease,andfewpatientscanbecured.Althoughmostpatientsreceivestandardizedsurgeryand
chemotherapy,thestatusofrecurrentdiseaseisheterogeneous.Thesiteofrecurrenceandthesurvivalintervalsafterrecurrenceare
also widely distributed. Among a number of factors, many clinical trials identiﬁed time to recurrence was the factor most related
to chemosensitivity at ﬁrst relapse. The current recommendation for platinum sensitive ovarian cancer is a carboplatin containing
combination chemotherapy. Generally, a single agent is chosen for platinum resistant ovarian cancer. Patients with single site
recurrence and a long disease free interval are candidates for secondary cytoreduction, which may provide longer survival. There
are several treatment choices at ﬁrst relapse, and disease status, chemotherapy-free interval, and the patient’s condition play a
major role in the decision making process.
1.Introduction
Ovariancancerhasthesecondhighestincidenceofanygyne-
cologic malignancy in western countries. In Asian countries,
ovarian cancer has the third highest incidence, but it is
rapidly increasing. In spite of recent progress in treatment
strategy, it is still the leading cause of death among cases
of gynecologic cancer. After recurrence, generally 70% of
advanced stage ovarian cancer relapses, and even in stage I or
II patients, the relapse rate is 20%–25%. The survival curve
after recurrence never plateaus, which means that the goal
of treatment for recurrent ovarian cancer is controlling the
disease and disease-related symptoms, limiting treatment-
related toxicity, and maintaining or improving quality of life
[1]. Nevertheless, the period up to ﬁrst relapse varies widely,
from a few months to more than 5 years. Several prognostic
factors have been reported, and clinical trials have provided
us with some treatment options. In this paper, patterns and
treatment for ovarian cancer at ﬁrst relapse are discussed.
2. PatternandClassiﬁcationof Recurrence
The median interval to ﬁrst recurrence is 18 to 24 months
in ovarian cancer. To clarify the prognostic factors and to
determine the treatment procedure, grouping of recurrent
patients was applied. They were distinguished by pretreat-
ment or initial treatment proﬁles, such as FIGO stage,
histologic type, and size of residuals. Furthermore, the status
at recurrence, such as time to recurrence, site of recurrence,
number of recurrent sites, and treatment procedure was
also tested as prognostic factors. Time to recurrence was
divided to three groups as follows: more than 12 months,
less than 6 months, and 6 to 12 months. Sites of ﬁrst
recurrence were divided to two groups, primary site (pelvis
and abdominal cavity), and other areas. The number of
recurrent sites was divided into two groups: single and
multiple. Treatment procedure was divided into surgery and
surgery plus chemotherapy.
Half of the recurrences occur at more than 12 months
from the end of the ﬁrst-line therapy, and one quarter
of all recurrences occur at less than 6 months. Regarding
recurrent sites, Table 1 shows the distribution of ﬁrst relapse
sites from our data on 112 recurrent cases. Fifty-ﬁve percent
of ﬁrst relapse was found at the primary site (pelvis or
abdomen); the rest was found at distant lesions similar
to previous reports [16] .T h e r ew a saw i d ev a r i e t yo f
recurrent sites, such as, retroperitoneal nodes, liver or
spleen, brain, and bone. There was no diﬀerence in ﬁrst
recurrent sites between early and advanced stage cancers
[17].2 Journal of Oncology
Table 1: Site distribution at ﬁrst relapse of ovarian cancer (n =
112).
Abdominal cavity 33 (29.4%)
∗
Pelvic cavity 29 (25.9%)
∗
Vaginal stump 17 (15.2%)
Retroperitoneal lymph node 8 (7.1%)
Superﬁcial lymph node 7 (6.3%)
Liver, spleen 7 (6.3%)
Bladder 3 (2.7%)
Bone 3 (2.7%)
Brain 2 (1.8%)
Lung 2 (1.8%)
Adrenal 1 (0.9%)
Select one main site in case of multilocated.
∗Recurrence at the primary site.
Kurume University 1990–2005.
An Italian study showed statistical signiﬁcance between
survival from recurrence and initial clinical stage (I, IIA
versus IIB–IV), residual disease after initial surgery (≤1cm
versus >1cm), time to recurrence (≤6 months versus 6–12
months, >12 months), and treatment at recurrence (surgery
plus chemotherapy versus others) by univariate analysis. In
multivariate analysis, residual disease and time to recurrence
were the only two independent prognostic factors after
recurrence. Conversely, histological type (serous versus non
serous), tumor grade (G1 versus G2, G3), number of recur-
rence sites (single versus multiple), and symptoms at recur-
rence (symptomatic versus asymptomatic) had no prognos-
tic relevance [16]. Hawkins identiﬁed predictive factors of
survival after ﬁrst relapse by time to progression (TTP)
(>593 days), original tumor grade ≤2, and performance
status ≤2 using tree model analysis. In this analysis, the good
responsegroupshowedlongersurvivalthantheintermediate
or poor response groups [18]. Data from our 110 recurrence
cases showed that time to recurrence (≤6 months versus
>6 months), the number of recurrence sites (single versus
multiple), and treatment at recurrence (chemotherapy plus
surgery and/or radiotherapy versus chemotherapy only) had
statistical signiﬁcance in survival after recurrence. On the
other hand, histologic type (serous or endometrioid versus
mucinous or clear cell) and initial clinical stage (I, II versus
III,IV)didnothaveanycorrelationwiththesurvivalinterval
after recurrence (Ushijima, unpublished data).
3. Treatment Option for Recurrence
3.1. Chemotherapy
3.1.1. Patient Selection. Regarding the secondary response of
platinum-based chemotherapy, Markman clariﬁed patients
with more than 24-month platinum free interval as showing
superior response compared to patients with between 5-
and 12-month interval (59% and 27%, resp.) [22]. Gore
reported that patients with at least an 18-month progression
free interval (PFI) showed a remarkably higher response
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Figure 1: Treatment free intervals and platinum sensitivity.
rate compared to patients with less than 18 months of
PFI (53% versus 17%) [23]. This theory was supported
by the following literature. It is generally accepted that
response to second-line chemotherapy correlates well with
PFI, from the end of initial treatment [24]. For the selection
of a chemotherapeutic regimen at ﬁrst relapse, patients are
categorized according to their estimated chemosensitivity
depending on PFI. Many studies have employed the 6-
month interval as the borderline when deﬁning the criteria
[25]. Figure 1 explains the criteria of platinum sensitivity.
Patients whose disease showed initial response to platinum
a n dr e c u r r e dh a v i n g>6 months PFI are deﬁned as platinum
sensitive.Patientswhosediseaseshowedresponsetoorstable
diseasepriortoplatinumtreatmentandwhorecurredwithin
6monthsofﬁnaltreatmentaredeﬁnedasplatinumresistant.
Foramore strictseparationof theplatinum sensitive disease,
patients with a more than 12-month interval are deﬁned as
highly sensitive disease and patients with 6 to 12 months
are considered intermediate sensitive disease [26]. Patients,
whose disease progressed during platinum treatment and
have less than 3-month platinum free interval, are deﬁned as
refractory disease, which means that these patients have very
little chance to respond to a platinum-based therapy [27].
3.1.2. Chemotherapy for Patients with Platinum Sensitive
Ovarian Cancer. The single use of carboplatin has been a
standard regimen for the patients with platinum sensitive
disease. A phase II trial on paclitaxel and carboplatin
combination for sensitive (≥6months) patients showed a
considerably high response rate (90%) and 9 months PFI
among 20 measurable and assessable patients [2]( Table 2).
The ICON4/AGO-Ovarian Cancer 2.2 trial which was a
large international phase III study showed that paclitaxel and
platinumcombinationhadastatisticallyhigherresponserate
and improved progression free survival (PFS) than conven-
tional platinum combination in 802 patients with platinum
sensitive disease [6]. Nevertheless, this trial had only 34%
of the patients who were treated with paclitaxel in the
front-line chemotherapy and included several combinations
in the treatment regimens as conventional platinum-based
chemotherapy.
A Spanish trial was conducted by more stringent design.
Eighty-one patients with platinum sensitive disease were
randomized to receive carboplatin (AUC: 5) alone as a
standard arm, or paclitaxel (175mg/m2) and carboplatinJournal of Oncology 3
Table 2: Phase II study results for platinum sensitive recurrent ovarian cancer.
PTX/CBDCA GEM/CBDCA PLD/CBDCA DTX/CBDCA
Author/group Rose et al. [2]d u B o i s e t a l . [ 3]P o w e r e t a l . [ 4]
∗ Ushijima et al. [5]
AGO WJGOG
Dose (mg/m2) 135/AUC 5-6 1000/AUC 4 30/AUC 5 70/AUC 5
Number of patients 20 25(16)
∗∗ 54 29
Response rate (%) 91 63 46 59
PFS (months) 9 10 10 11
OS (months) 10 18 19.1 NA
PTX: paclitaxel; CBOCA: carboplatin; GEM: gemcitabine.
PLD: pegylated liposomal doxorubicin.
PFS: progression free interval; PS: overall survival.
∗Patients who recur within 6 to 12 months.
∗∗Patients with measurable disease.
NA: not applicable.
(AUC: 5) as an experimental arm. More than 80% of
patients received paclitaxel previously. Those who were
treated with paclitaxel and carboplatin had a signiﬁcantly
higher response rate (75.6% versus 50.0%) and a PFS that
was4monthslongerthanthosetreatedwithcarboplatinonly
[7]. Furthermore, the platinum and paclitaxel combination
did not increase toxicity except moderate neurotoxicity.
These results suggested the beneﬁts of a paclitaxel and
platinum combination and it became the standard treatment
of choice for the patients with platinum sensitive disease
(Table 3).
A phase I, II study of gemcitabine and carboplatin com-
binationshowed62.5%ofobjectiveresponseinpatientswith
platinum sensitive ovarian cancer [3]( Table 2). According to
this result, a large randomized study was conducted by AGO,
NCICCTG,EORTCintergrouptrialtocomparegemcitabine
(1.000mg/m2) plus carboplatin (AUC: 4) with carboplatin
(AUC: 5) alone for platinum sensitive ovarian cancer. In
total, 356 patients were recruited and higher response rates
wereshowninthegemcitabinepluscarboplatincombination
including a higher CR rate (14.6% versus 6.2%) and a
signiﬁcantly longer PFS (8.6 months versus 5.8 months).
There was no diﬀerence in nonhematologic toxicities, but
grades 3 and 4 hematologic toxicities were greater with the
combination [8]( Table 2).
Pegylated liposomal doxorubicin (PLD) is one of the
alternatives for platinum resistant ovarian cancer. A phase
II study of PLD (30mg/m2) plus carboplatin (AUC: 5)
q/4weeks combination chemotherapy showed a 46% objec-
tive response rate for the patients who recur within six
to twelve months [4]. A randomized phase III study of
PLD (30mg/m2) plus carboplatin (AUC: 5) q/4w versus
carboplatin (AUC: 5) q/4w alone for platinum sensitive
ovarian cancer was done by SWOG. The PLD containing
regimen showed a 4-month longer PFS (12 months versus
8 months). The lack of incidence of carboplatin-related
allergic reaction in the PLD-treated patients may be an
additional beneﬁt of this combination [9]. Gynecologic
Cancer Intergroup (GCIG) conducted a large phase III
study for patients with taxane pretreated sensitive relapse
disease, whichconsisted ofPLD(30mg/m2)pluscarboplatin
(AUC: 5) q/4weeks (CD) versus retreatment by paclitaxel
(175mg/m2) plus carboplatin (AUC: 5) q/3weeks (CP)
(CALYPSO study), and the result was presented at ASCO
in 2009. The number of patients was 466 in CD and
508 in CP. When comparing median PFS, CD showed
statistically longer PFS (11.3 months versus 9.4 months).
These two regimens had diﬀerent toxicity proﬁles. CD had
more incidences of thrombocytopenia and palmar-plantar
erythrodysesthesia (PPE). Nevertheless, CD had extremely
less incidence of Grade 4 neutropenia, Grade 2 alopecia,
Grade 2–4 neurotoxicity, and carboplatin hypersensitivity
reaction, which resulted in signiﬁcantly less incidence of
discontinuation of treatment by toxicity than CP. This
combination may be a good option for platinum or taxane
sensitive relapse [10].
Docetaxel showed similar response to paclitaxel and a
diﬀerent toxicity proﬁle in ﬁrst line chemotherapy [28]. The
Japanese group conducted a phase II trial with docetaxel
(70mg/m2) and carboplatin (AUC: 5) combination for plat-
inum sensitive patients. The objective response rate was 59%
(17/29, including 5 CR) in 29 evaluable patients (Table 2).
They showed 46% sensory neurotoxicity and only 7% motor
neurotoxicity, without any grade 3 or 4 neurotoxicity, even
though most patients were previously treated by paclitaxel
[5]. According to this result, a new trial which consisted
of biweekly docetaxel (35mg/m2) with bolus carboplatin
(AUC: 5) repeated every 4 weeks is now ongoing. We can
expect a similar response to bolus DC treatment with less
hematologic toxicity.
Insummary,acarboplatin-basedcombinationisstrongly
recommended for patients with platinum sensitive disease
rather than carboplatin monotherapy. Paclitaxel with carbo-
platin is the most frequently used combination and showed
favorable result for these patients. Nevertheless, alternative
combinations of gemcitabine or PLD with carboplatin
have responses and prolonged survival rates similar to
paclitaxel and carboplatin with diﬀerent toxicity proﬁles.
Gemcitabine combination showed similar bone marrow
t o x i c i t yb u tl e s sn e u r o p a t h yo ra l o p e c i a .P L Dc o m b i n a t i o n
showed less neurotoxicity or bone marrow toxicity, but more
PPE.4 Journal of Oncology
Table 3: Phase III study results for platinum sensitive recurrent ovarian cancer.
PTX/CBOCA (COOP) PTX/CBOCA GEM/CBOCA PLO/CBOCA PLO/CBOCA
versus Pt combination versus CBDCA versus CBDCA versus CBDCA versus PTX/CBOCA
Dose (mg/m2) 175–185/ AUC 5 (50–75) 175/AUC 5 1000/AUC 4 30/AUC 5 30/AUC 5
versus AUC 5 (50–75) versus AUC 5 versus AUC 5 versus AUC 5 versus 175/AUC 5
Author Gonz´ alez-Mart´ ın et al. Pﬁsterer et al. Alberts et al. Pujiade-Lauraine et al.
ICON4/ [6]G E I C O [ 7]A G O O V A R , [ 8]S W O G [ 9]G C l G [ 10]
Study group AGO-OVAR2.2 NCIC CTG, EORTC GCG
Number of patients 392 versus 410 41 versus 40 178 versus 178 31 versus 30 466 versus 508
Response rate (%) 66 versus 54 75.6 versus 50.0∗ 47.2 versus 30.9∗ 52 versus 29 NA
PFS (months) 12 versus 9∗ 12.2 versus 8.4∗ 8.6 versus 5.8∗ 12 versus 8∗ 11.3 versus 9.4∗
OS (months) 29 versus 24
∗ NA 18 versus 17.3 26 versus 18
∗ NA
PTX: paclitaxel; PT: cisplatin or carboplatin.
CBDCA: carboplatin; GEM: gemcitabine; PLD: pegylated Iiposomal doxorubicin.
PFS: progression free interval; PS: overall survival.
NA: not applicable.
∗Statistically signiﬁcant.
Table 4: Study result for platinum resistant recurrent ovarian cancer (single agent).
PLD GEM Topotecan PLD versus PLO versus GEM
Topotecan
Dose 50 mg/m2/4w 1g/m2 1.5mg/m2 d1–5/3w 50mg/m2/4w 50mg/m2/4w
d1.8.15/4w (1 mg/m2/3w) 1.5mg/m2 for 5 d/3w 19/d1.8/3w
Author Gordon et al. [31] Markman [11] Bookman et al. [15] O’Malley et al. [13]M u t c h e t a l . [ 14]
(Rodriguez et al. [36])
Number of patients 82 51 112 (37) 130 versus 124 96 versus 99
Response rate
CR + PR (%) 18.3 16 12.4 (22 ) 12.3 versus 6.5 8.3 versus 6.1
+SD (%) 66.1 NA NA(44) 40 versus 49.2 46.9 versus 60.6
Most frequent
Adverse eﬀect PPE neutropenia neutropenia PPE/neutropenia fatigue/fatigue
PFS (weeks) 17 16 12.1 (18) 9.1 versus 13.6 12.4 versus 14.4
OS (weeks) 15 (months) 47 (NA) 35.6 versus 41.3 50.8 versus 54
PPE: palmar-plantar erythrodysesthesia.
3.1.3. Chemotherapy for Patients with Platinum Resistant
Ovarian Cancer. M a n yp h a s eI It r i a l so fs i n g l ea g e n t sf o r
patients with platinum resistant disease showed at most
only a 5%–20% response rate (Table 4). Therefore, duration
of disease control and low incidence of toxicity should be
an important factor in choosing the proper drugs [29].
PLD demonstrated a response in the treatment of recurrent
ovarian cancer in some phase II studies [30, 31]. Although
the recommended dose of PLD is 50mg/m2 q/4weeks, a
reduceddose(40mg/m2 q/4weeks)showedalowerincidence
of PPE which is schedule limiting toxicity. So, a modiﬁed
dose 40mg/m2 q/4weeks may be used for patients with
platinumresistantovariancancertominimizeadverseeﬀects
[32].PLDisrecognizedastheﬁrstchoicenonplatinumagent
for patients with relapse, who have failed ﬁrst-line therapy,
or who cannot tolerate platinum retreatment due to toxicity
[33].
Gemcitabine has less toxicity except for manageable
neutropenia. Single use gemcitabine (1000mg/m2 on day
1, 8, and 15 q/4w) is well tolerated and showed 16% of
partial response in 51 platinum-paclitaxel refractory ovarian
cancer (Table 4)[ 11]. Dose limiting toxicity is bone marrow
suppression; so starting at reduced doses (800mg/m2)f o r
heavily pretreated patients is reasonable [11]. A randomized
phase III study comparing gemcitabine (1000mg/m2 on
day 1, 8 q/3w) with PLD (50mg/m2 q/4w) in platinum
resistant patients showed similar response and PFS. Fatigue
(grade2) is frequently the worst toxicity, nausea (grade3)
and neutropenia (grade3 and 4) are also statistically frequent
in gemcitabine, and PPE is more frequent in PLD [14]Journal of Oncology 5
Table 5: Study result for platinum resistant recurrent ovarian
cancer (combination).
GEM/weekly
PTX GEM/PLD PLD
/Topotecan
Dose (mg/m2) 1000/80 1000/30 30/1
day 1.8. 15/4w day 1.8/day
l/3w
day l/day
l–5/3w
Author Garcia et al.
[12]
Ferrandina et
al. [19]
Verhaar-
Langereis et al.
[20]
Number of
patients 35 66 27
Response rate
CR + PR (%) 40 21.6 28
+ SD (%) 77 53.9 72
PFS (months) 5.7 20 weeks 30 weeks
OS (months) 13.1 50 weeks 41 weeks
(Table 4). The diﬀerent mechanisms and noncross-resistance
of gemcitabine can be expected to overcome drug resistance
in combination with other nonplatinum drugs [34]. A com-
binationofgemcitabine(1000mg/m2)withweeklypaclitaxel
(80mg/m2) on days 1, 8 and 15 q/4w showed a 40% response
rate and the median PFS was 5.7 months for 35 patients
with platinum resistant disease [12]. A large multicenter
phase II study of combination of PLD (30mg/m2)d a y1
and gemcitabine (1000mg/m2)d a y s1a n d8e v e r y3w e e k s
showed a 22% overall response and a 32% stable disease for
patients with platinum resistant disease. In that study, the
lower PLD dose might contribute to the very low incidence
of PPE (Table 5)[ 19].
Topoisomerase inhibitors, topotecan, irinotecan, and
oral etoposide can also be used for platinum resistant
disease. The standard treatment of topotecan is 1.5mg/m2
for ﬁve consecutive days, every 3 weeks. The response
rate for platinum resistant ovarian cancer was 12%–14%
[15, 35]. High bone marrow toxicity was seen (82% of
patients with Grade 4 neutropenia) in heavily pretreated
patients [19]. Recently, a lower dose (1.0mg/m2)5 - d a yq / 3 w
protocol [36], weekly schedule (2.5mg/m2 days 1, 8, 15
q/4w) [13], or 3-day schedule (1.5mg/m2 days 1–3 q/3w)
[37] improved treatment tolerability for heavily pretreated
patients (Table 4). The combination of lower dose of PLD
(30mg/m2)andt o pot ecan(1mg/m 2 fordays1–5)wastested
for platinum resistant ovarian cancer. Although relatively
higher response rate (28%) was seen in a phase II study,
severebone marrow toxicity (grade3/4 thrombocytopenia in
41% of cases) limited further clinical use (Table 5)[ 20].
A randomized phase III study for topotecan and PLD
for refractory or recurrent ovarian cancer was conducted.
The PFS rates were similar between two arms. In patients
Table 6: Recommendation for secondary cytoreduction based on
disease free interval and number of recurrence site.
Disease free Single site Multiple site Carcinomatosis
interval no carcinomatosis
6–12 Mo oﬀer SC consider SC No SC
12–30 Mo oﬀer SC oﬀer SC consider SC
>30 Mo oﬀer SC oﬀer SC oﬀer SC
DFI: disease free interval. SC: secondary cytoreduction. Chi et al. [21].
with platinum sensitive disease, PLD was demonstrated to
be signiﬁcantly superior to topotecan in overall survival. On
the other hand, in the platinum-refractory subgroup there
wasnostatisticallysigniﬁcantsurvivaltrendinfavorofeither
liposomal doxorubicin or topotecan (Table 4)[ 38].
4. Surgery
Complete response by chemotherapy for recurrent ovarian
cancer is rare, and shrinkage of the tumor does not always
ensure prolongation of survival. A surgical approach may
bring clinical beneﬁt to some patients. Surgery for clinical
recurrence is deﬁned as secondary cytoreductive surgery,
similar to surgery for persistent disease at the completion of
chemotherapy. In multivariate analysis, disease free interval,
the number of sites of recurrence, and residual disease after
secondary cytoreduction were factors found to inﬂuence
prognosis. The patients with the longer disease free interval
(>30 months) and a single site of recurrence were most likely
to reap the beneﬁts of secondary cytoreduction (Table 6)
[21] .Al o n g e rp e r i o do fP F Sa n dc o m p l e t er e s e c t i o na t
secondary cytoreductive surgery are common favorable
prognostic factors [39–41]. Nevertheless, the surgical result
is dependent on the number of sites and the skill of the
surgeon. Onda et al. proposed four prognostic factors as
follows: >12 months PFS, no liver metastasis, solitary tumor,
and <6cm tumor size. Patients with three or all four of these
factorswhoreceivedcompletesurgicalresectionatsecondary
cytoreduction showed a favorable prognosis [42].
At secondary reduction, bowel or other organ resec-
tions are often also performed. More than 30% of surg-
eries included bowel resection [21], and some of them
accompanied considerable morbidity, such as colostomy or
pelvic exenteration [40]. On the other hand, patients with
longer PFS are also expected high response to second-
line chemotherapy. Therefore, careful consideration must be
made when deciding which strategy, surgery, or chemother-
apy to use to most beneﬁt each patient.
5. Conclusion
Recurrence of ovarian cancer is a lethal and chronic
disease. Nevertheless, patients with recurrent platinum-
sensitive ovarian cancer may have increased response rates
and longer PFS when treated with combination platinum-
based chemotherapy compared to carboplatin alone. Most
recurrent patients with platinum resistant disease have
little chance for a long PFS, but less toxic treatment may6 Journal of Oncology
contribute to extending their survival interval. Complete
secondary cytoreduction combined with further adjuvant
therapy at the time of relapse may improve clinical outcome
in selected patients. There are several treatment choices from
ﬁrst relapse to terminal state; however these choices cannot
be made uniformly. They should be decided on an individual
basis depending directly on the patients’ condition.
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